Petco Health & Wellness Company, Inc.: Form 10-Q for the period ended Nov 2, 2024
Filed with the SEC on Dec 6, 2024 and accepted by EDGAR at Dec 6, 2024, 21:05 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2024-11-02. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2024-08-04 to 2024-11-02 | $1.51bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2024-02-04 to 2024-11-02 | $4.56bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2024-08-04 to 2024-11-02 | $935.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2024-02-04 to 2024-11-02 | $2.83bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2024-08-04 to 2024-11-02 | $575.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2024-02-04 to 2024-11-02 | $1.74bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2024-08-04 to 2024-11-02 | $571.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2024-02-04 to 2024-11-02 | $1.75bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2024-08-04 to 2024-11-02 | $4.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2024-02-04 to 2024-11-02 | −$10.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2024-08-04 to 2024-11-02 | −$857.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2024-02-04 to 2024-11-02 | −$10.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2024-08-04 to 2024-11-02 | −$16.7m | us-gaap:NetIncomeLoss |
| Net income | 9 months2024-02-04 to 2024-11-02 | −$88.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2024-08-04 to 2024-11-02 | −$0.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2024-02-04 to 2024-11-02 | −$0.32 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2024-08-04 to 2024-11-02 | −$0.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2024-02-04 to 2024-11-02 | −$0.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2024-08-04 to 2024-11-02 | 274,495,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2024-02-04 to 2024-11-02 | 272,446,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2024-02-04 to 2024-11-02 | $81.7m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2024-02-04 to 2024-11-02 | $91.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2024-11-02 | $116.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2024-11-02 | $931.8m | us-gaap:AssetsCurrent |
| Total assets | At period end2024-11-02 | $5.21bn | us-gaap:Assets |
| Current liabilities | At period end2024-11-02 | $1.11bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2024-11-02 | $4.09bn | us-gaap:Liabilities |
| Long-term debt | At period end2024-11-02 | $1.58bn | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2024-11-02 | $1.12bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000950170-24-134077. Last ingested by Listed: Oct 24, 2026, 15:15 ET. Listed shows no prices and gives no investment advice.